Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
RegulatoryWatchNotablemateriality 61 out of 100
What happened
FactPendency of Litigation(s)/dispute(s) or the outcome impacting the Company.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Order Book
DelayedEarlierFY25
We are pleased with our FY25 performance, which underscores the strength of our strategy and execution.
NowQ1 FY27
Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting from now.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe stated timeline moved by 16 quarter(s) (earlier to FY29).confidence 60%
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
- Aequitas alone, we are looking at around Rs.100 crores of business within two and a half years' time, starting (management committed by FY29)
- Starting with a revenue base of Rs.53 crores, we are targeting Rs.10 crores EBITDA by year two post-integratio (management committed by FY27)
Evidence
- Jagsonpal Pharmaceuticals Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- LITIGATION base 56; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%